Document is current
Any future updates will be listed below
-
Authors
Sayiner, Mehmet
Arshad, Tamoore
Golabi, Pegah
Paik, James
Farhat, Freba
Younossi, Zobair M.
- License Information
-
More Information
Article History
Received: 23 December 2019
Accepted: 21 March 2020
First Online: 16 April 2020
Compliance with ethical standards
:
: Dr. Younossi is a consultant to BMS, Gilead, Intercept, NovoNordisk. Novartis, Terns, Merck, Viking, and Shinogi. All other authors have no conflict of interest to disclose. Mehmet Sayiner, Tamoore Arshad, Pegah Golabi, James Paik, Freba Farhat, Zobair M. Younossi read and approved the final version of the manuscript.
: Zobair M. Younossi is the guarantor of this work, and had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
: This article does not contain any studies with animals performed by any of the authors. This study was approved as “exempt” by the Inova Health Systems Internal Review Board located in Falls Church, VA, prior to the start of the study.
